Delivery of TLR7 agonists by Deep-Primed (TM) T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity

Austin Boesch, Vasily Rybakin, Nathan Westcott, Ji Young Hwang, Kira Røpke Jørgensen, Rasmus Lassen, Martin Kisha Kræmer, Martin Bak, Gael Veiga, Jonas Bruun, Carlos Tassa, Harrison Rodts, Manny Sequeira, Glenn Leary, Santina Caruso, Becker Hewes, Jonathan Fitzgerald, Karsten Sauer, Thomas Lars Andresen

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article numberP671
JournalJournal for ImmunoTherapy of Cancer
Volume7
Issue numberSuppl. 1
ISSN2051-1426
Publication statusPublished - 2019
Event34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019) - Gaylord National Hotel & Convention Center, National Harbour, United States
Duration: 6 Nov 201910 Nov 2019
https://www.sitcancer.org/2019/home

Conference

Conference34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019)
LocationGaylord National Hotel & Convention Center
CountryUnited States
CityNational Harbour
Period06/11/201910/11/2019
Internet address

Cite this

Boesch, A., Rybakin, V., Westcott, N., Hwang, J. Y., Jørgensen, K. R., Lassen, R., Kræmer, M. K., Bak, M., Veiga, G., Bruun, J., Tassa, C., Rodts, H., Sequeira, M., Leary, G., Caruso, S., Hewes, B., Fitzgerald, J., Sauer, K., & Andresen, T. L. (2019). Delivery of TLR7 agonists by Deep-Primed (TM) T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity. Journal for ImmunoTherapy of Cancer, 7(Suppl. 1), [P671].